Devicare, a leading pharmaceutical company in the field of urology and a member of Catalonia.health, has announced the acquisition of IP-6 International, Inc., a renowned North American nutritional supplement company and manufacturer of the IP6 Gold® brand. This operation represents Devicare's first acquisition outside Spain and constitutes a significant milestone in its international growth strategy.
Strategic Entry into the North American Market
The acquisition allows Devicare to strategically enter the United States market, the world's largest and most dynamic pharmaceutical and nutraceutical market. The company aims to leverage its solid scientific expertise and commercial structure to expand IP-6 International's global presence, while introducing its extensive portfolio of innovative urology solutions to the North American market.
According to Rosendo Garganta, CEO of Devicare, "IP-6 International is a company with a proven track record and an excellent reputation for the quality and scientific rigor of its products, manufactured in the United States. This acquisition is a natural extension of our mission to offer science-based health solutions to patients and healthcare professionals around the world."
Product and Expertise Synergy
Founded in 2002, IP-6 International has achieved global recognition thanks to its flagship product, IP6 Gold®, a premium formula that combines inositol hexaphosphate (IP6) —a compound widely known to Devicare and used in many of its products— with inositol derived from non-GMO rice bran. Manufactured under strict quality standards, IP6 Gold® enjoys the trust of both healthcare professionals and consumers.
This acquisition strengthens Devicare's portfolio with a highly complementary brand from a scientific standpoint and represents a strategic lever for expansion into North America and other markets.
Vision for the Future
The acquisition lays the foundation for Devicare to consolidate its presence in the United States and use this strategic market as a platform for its global expansion, reinforcing its mission to improve clinical outcomes in urolithiasis and other urinary health areas.
With this operation, together with its current portfolio and recent international launches, Devicare continues to strengthen its leadership position in urology.
Comments